Company Analysis
Sign in

Ascendis Pharma A/S (ASND)

Nasdaq: ASND · Pharmaceutical Preparations · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.2
◀ Past 7.0● Present 6.0▶ Future 5.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Ascendis Pharma A/S

Nine metrics read from its own filings, by tense
Headline grade
6.2/10
◀ Past7.030% of the headline
● Present6.040% of the headline
▶ Future5.530% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.0/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Ascendis Pharma A/S' filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
5.8/10

What has it actually done, year after year?

+75.3% a year over 10 filed years; profitable in 0 of 10.

weight 45% of this tense · 58th percentile among 323 sector filers · read for its customers

From the record

Ascendis Pharma A/S' 10 filed years say what it did: revenue went from EUR 5 million in fiscal 2016 to EUR 720 million in fiscal 2025, up 75.3% a year; it rose in 7 of 9 years; the deepest fall was 67% from fiscal 2016 to fiscal 2017; net income was positive in 0 of 10 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span75.3%top 14% of its family
  • the share of years revenue rosetop 28% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak66.8%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
7.8/10

How has it treated the people who own it?

SI estimate 7.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 78th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 22% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascendis Pharma A/S's shareholder treatment is put at 7.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 22% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

6.0/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
5.3/10

Is it financially healthy right now?

Leverage 112%: owes 112¢ per asset dollar.

weight 45% of this tense · 53rd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Ascendis Pharma A/S' shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 48 cents per dollar of everything the company owns. Leverage: it owed about 112 cents per dollar of assets, and net share issuance: its share count grew 4.7% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 9% of its family
  • gross profit against assetstop 20% of its family
  • the share count against the year beforetop 29% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
7.7/10

How strong is its position in its industry?

top 23% of 315 in its family; net margin -31.7%.

weight 33% of this tense · 77th percentile among 315 sector filers · read for its customers

From the record

Ascendis Pharma A/S' standing among 315 graded names in its industry family: revenue of EUR 720 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -31.7% ranks in the top 37%; revenue growth of 141.4% a year over the last 3 filed years ranks in the top 9% (its annual reports).

What it rests on

  • net margin-31.7%top 37% of its family
  • three-year revenue growth141.4%top 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
family median, 371 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Ascendis Pharma A/S's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

5.5/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.1/10

How much room does it have to grow?

top 49% of 273 in its family for room to expand.

weight 45% of this tense · 51st percentile among 273 sector filers · read for itself

From the record

Ascendis Pharma A/S' room to grow, from the newest filed statements (fiscal 2025): cash of EUR 616 million against debt of EUR 720 million leaves -8% of its assets as net cash, bottom 11% of its family; cash from operations less capital spending is 7.5% of revenue (top 23%); a gross margin of 86.8% (top 24%); research spending of 42.2% of revenue (bottom 40%) (its annual report).

What it rests on

  • cash less debt against assets-8.0%bottom 11% of its family
  • cash from operations less capital spending against revenue7.5%top 23% of its family
  • gross margin86.8%top 24% of its family
  • research spending against revenue42.2%bottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
5.8/10

What could actually drive growth from here?

top 42% of 306 in its family for growth drivers.

weight 33% of this tense · 58th percentile among 306 sector filers · read for its customers

From the record

Ascendis Pharma A/S' growth drivers, from the filed years to fiscal 2025: revenue grew 141.4% a year over the last three filed years against 75.3% over all 10, speeding up (top 7% of its family); the newest year grew 98.1% (top 17%); research spending grew -7.2% a year (bottom 36%); capital spending grew -50.3% a year (bottom 20%) (its annual reports). Ascendis Pharma A/S tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+66.1 points a yeartop 7% of its family
  • the newest year's revenue growth98.1%top 17% of its family
  • three-year growth of research spending-7.2%bottom 36% of its family
  • three-year growth of capital spending-50.3%bottom 20% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
6.0/10

Did its newest year beat what its own record pointed to?

top 41% of 233 in its family for expectations against reality.

weight 22% of this tense · 59th percentile among 233 sector filers · read for its shareholders

From the record

Ascendis Pharma A/S' newest year against its own record: revenue of EUR 720 million in fiscal 2025 came in 25.7% below the EUR 969 million its prior three years' pace pointed to (bottom 30% of its family); net income of EUR 228 million against a prior three-year average of EUR 481 million (top 31%); a net margin of -31.7% against losses larger than its revenue before (top 21%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-25.7%bottom 30% of its family
  • net income against the prior three years' average+53%top 31% of its family
  • net margin against its prior averageup more than 100 pointstop 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ASND · research, not advice